

Myung-Ju Ahn

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4969855/myung-ju-ahn-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

362
papers

10,456
citations

53
h-index

91
g-index

398
ext. papers

14,309
ext. citations

4.3
avg, IF

6.31
L-index

#	Paper	IF	Citations
362	ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non-small cell lung cancer.. <i>Investigational New Drugs</i> , 2022 , 40, 265	4.3	0
361	Clinical Value of Surveillance F-fluorodeoxyglucose PET/CT for Detecting Unsuspected Recurrence or Second Primary Cancer in Non-Small Cell Lung Cancer after Curative Therapy.. <i>Cancers</i> , 2022 , 14,	6.6	2
360	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with Fusion-Positive Solid Tumors.. <i>Clinical Cancer Research</i> , 2022 ,	12.9	10
359	Dynamics of circulating immune cells during chemoradiotherapy in patients with non-small cell lung cancer support earlier administration of anti-PD-1/PD-L1 therapy.. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022 ,	4	1
358	Clinical Characteristics and Outcomes in Advanced -Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005).. <i>JTO Clinical and Research Reports</i> , 2022 , 3, 100261	1.4	0
357	Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor.. <i>Oncology</i> , 2022 , 1-10	3.6	
356	Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial.. <i>Journal of Thoracic Oncology</i> , 2022 ,	8.9	3
355	Clinical Utility of Plasma Cell-Free DNA EGFR Mutation Analysis in Treatment-Naïve Stage IV Non-Small Cell Lung Cancer Patients.. <i>Journal of Clinical Medicine</i> , 2022 , 11,	5.1	1
354	Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102010	2.2	4
353	Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer.. <i>European Journal of Cancer</i> , 2022 , 169, 42-53	7.5	0
352	A Phase 1/2 Study of Lazertinib 240 mg in Patients with Advanced EGFR T790M-Positive Non-Small Cell Lung Cancer After Prior EGFR Tyrosine Kinase Inhibitors.. <i>Journal of Thoracic Oncology</i> , 2021 ,	8.9	4
351	Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience. <i>European Journal of Cancer</i> , 2021 , 159, 167-173	7.5	2
350	457 KEYNOTE-495/KeyImpaCT: interim analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for non-small cell lung cancer (NSCLC) 2021 , 9, A485-A485		
349	Prognosis of pulmonary lymphangitic carcinomatosis in patients with non-small cell lung cancer.. <i>Translational Lung Cancer Research</i> , 2021 , 10, 4130-4140	4.4	1
348	Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment.. <i>Translational Lung Cancer Research</i> , 2021 , 10, 4209-4220	4.4	0
347	Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes.. <i>Cancer Epidemiology</i> , 2021 , 76, 102080	2.8	0
346	Real-time automatically updated data warehouse in healthcare (ROOT): an innovative and automated data collection system. <i>Translational Lung Cancer Research</i> , 2021 , 10, 3865-3874	4.4	

345	Induction chemotherapy followed by concurrent chemoradiotherapy versus CCRT for locally advanced hypopharynx and base of tongue cancer. <i>Korean Journal of Internal Medicine</i> , 2021 , 36, S217-S224	2.5	3
344	Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery. <i>Journal of Korean Neurosurgical Society</i> , 2021 , 64, 271-281	2.3	4
343	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic Fusion-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1253-1263	2.2	22
342	High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program. <i>Cancer</i> , 2021 , 127, 3019-3028	6.4	6
341	A phase II study of palbociclib for recurrent or refractory advanced thymic epithelial tumor (KCSG LU17-21).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 8576-8576	2.2	1
340	Brigatinib (BRG) in ALK+ crizotinib (CRZ)-refractory non-small cell lung cancer (NSCLC): Final results of the phase 1/2 and phase 2 (ALTA) trials.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9071-9071	2.2	1
339	ALTA-2: Phase III study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib. <i>Future Oncology</i> , 2021 , 17, 1709-1719	3.6	4
338	The clinical efficacy of olaparib monotherapy or combination with ceralasertib (AZD6738) in relapsed small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 8562-8562	2.2	0
337	The AIM-HN Study: A pivotal study evaluating the efficacy of tipifarnib in patients with recurrent or metastatic head and neck squamous cell carcinoma with HRAS mutations.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS6087-TPS6087	2.2	0
336	Multimodal treatments and outcomes for anaplastic thyroid cancer before and after tyrosine kinase inhibitor therapy: a real-world experience. <i>European Journal of Endocrinology</i> , 2021 , 184, 837-845	6.5	4
335	Global longitudinal assessment of treatment outcomes in recurrent/metastatic nasopharyngeal carcinoma: GLANCE-NPC study. <i>Future Oncology</i> , 2021 , 17, 2015-2025	3.6	1
334	Tipifarnib in Head and Neck Squamous Cell Carcinoma With Mutations. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1856-1864	2.2	31
333	Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC). <i>Clinical Lung Cancer</i> , 2021 , 22, 301-312.e8	4.9	3
332	PD-1 blockade-unresponsive human tumor-infiltrating CD8 T cells are marked by loss of CD28 expression and rescued by IL-15. <i>Cellular and Molecular Immunology</i> , 2021 , 18, 385-397	15.4	10
331	Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 171-181	9.7	12
330	Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 764-773	8.9	47
329	Three-year follow-up of ATTRACTION-3: A phase III study of nivolumab (Nivo) in patients with advanced esophageal squamous cell carcinoma (ESCC) that is refractory or intolerant to previous chemotherapy.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 204-204	2.2	2
328	Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 147, 2459-2469	4.9	1

327	Dynamic contrast-enhanced MRI for response evaluation of non-small cell lung cancer in therapy with epidermal growth factor receptor tyrosine kinase inhibitors: a pilot study. <i>Annals of Palliative Medicine</i> , 2021 , 10, 1589-1598	1.7	1
326	A Response to the Letter to the Editor: Osimertinib Leads the Way Towards Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases. <i>Journal of Thoracic Oncology</i> , 2021 , 16, e14	8.9	
325	Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitors. <i>Translational Lung Cancer Research</i> , 2021 , 10, 878-888	4.4	3
324	Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. <i>European Journal of Immunology</i> , 2021 , 51, 956-964	6.1	4
323	Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12. <i>Cancer Research and Treatment</i> , 2021 , 53, 671-677	5.2	4
322	Complementary Use of Presepsin with the Sepsis-3 Criteria Improved Identification of High-Risk Patients with Suspected Sepsis. <i>Biomedicines</i> , 2021 , 9,	4.8	1
321	Cardiac Safety Assessment of Lazertinib: Findings From Patients With Mutation-Positive Advanced NSCLC and Preclinical Studies. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100224	1.4	0
320	Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer. <i>Lung Cancer</i> , 2021 , 159, 162-170	5.9	1
319	Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 2091-2108	8.9	19
318	Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7/8 agonist in lung cancer model. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2021 , 37, 102415	6	5
317	Brain metastases in patients with oncogenic-driven non-small cell lung cancer: Pros and cons for early radiotherapy. <i>Cancer Treatment Reviews</i> , 2021 , 100, 102291	14.4	3
316	Regulatory (FoxP3) T cells and TGF- β predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer. <i>Scientific Reports</i> , 2020 , 10, 18994	4.9	17
315	Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With Exon 14 Skipping. <i>In Vivo</i> , 2020 , 34, 1399-1406	2.3	4
314	Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1119-1136	8.9	51
313	Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. <i>Nature Communications</i> , 2020 , 11, 2285	17.4	163
312	Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma. <i>European Journal of Cancer</i> , 2020 , 132, 150-158	7.5	14
311	Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer. <i>Lung Cancer</i> , 2020 , 146, 23-29	5.9	28
310	Adjuvant therapy in stage IIIA-N2 non-small cell lung cancer after neoadjuvant concurrent chemoradiotherapy followed by surgery. <i>Journal of Thoracic Disease</i> , 2020 , 12, 2602-2613	2.6	3

309	MDSC subtypes and CD39 expression on CD8 T cells predict the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLC. <i>European Journal of Immunology</i> , 2020 , 50, 1810-1819	6.1	16
308	Ten-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea (Realtime automatically updated data warehouse in health care; UNIVERSE-ROOT study). <i>Lung Cancer</i> , 2020 , 146, 112-119	5.9	3
307	Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer. <i>Cancer</i> , 2020 , 126, 2704-2712	6.4	14
306	Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 914-947	8.9	71
305	Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy. <i>Cancer</i> , 2020 , 126, 4002-4012	6.4	4
304	PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence. <i>Cancer Medicine</i> , 2020 , 9, 2352-2362	4.8	14
303	Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity. <i>Nature Communications</i> , 2020 , 11, 951	17.4	14
302	Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment. <i>Oncotarget</i> , 2020 , 11, 1722023	7.2	13
301	Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma. <i>PLoS ONE</i> , 2020 , 15, e0229299	3.7	6
300	Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice. <i>Japanese Journal of Clinical Oncology</i> , 2020 , 50, 594-601	2.8	6
299	Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study. <i>Oral Oncology</i> , 2020 , 102, 104526	4.4	19
298	Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors. <i>BMC Ophthalmology</i> , 2020 , 20, 19	2.3	16
297	Impact of diffusing lung capacity before and after neoadjuvant concurrent chemoradiation on postoperative pulmonary complications among patients with stage IIIA/N2 non-small-cell lung cancer. <i>Respiratory Research</i> , 2020 , 21, 13	7.3	4
296	Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. <i>Lancet Oncology</i> , 2020 , 21, 373-386	21.7	148
295	Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 661-674	13.4	205
294	Efficacy and safety of entrectinib in patients (pts) with NTRK-fusion positive (NTRK-fp) solid tumors: An updated integrated analysis.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3605-3605	2.2	22
293	Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 6503-6503	2.2	10
292	Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9517-9517	2.2	12

291	ctDNA resistance landscape of lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9601-9601	2.2	1
290	A phase II open-label, multicenter, study to evaluate the efficacy and safety of rivoceranib in subjects with recurrent or metastatic adenoid cystic carcinoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS6597-TPS6597	2.2	0
289	Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea. <i>Cancer Research and Treatment</i> , 2020 , 52, 292-300	5.2	8
288	Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies. <i>Cancer Research and Treatment</i> , 2020 , 52, 284-291	5.2	2
287	Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea. <i>Cancer Research and Treatment</i> , 2020 , 52, 1112-1119	5.2	4
286	EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation. <i>Cancer Research and Treatment</i> , 2020 , 52, 1288-1290	5.2	4
285	Cancer-Related Stroke: An Emerging Subtype of Ischemic Stroke with Unique Pathomechanisms. <i>Journal of Stroke</i> , 2020 , 22, 1-10	5.6	36
284	A phase III, open-label, randomized study of atezolizumab in combination with carboplatin + paclitaxel + bevacizumab compared with pemetrexed + cisplatin or carboplatin with stage IV non-squamous non-small cell lung cancer (NSCLC) with activating EGFR mutation or ALK translocation (ATLAS Trial). <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS9636-TPS9636	2.2	1
283	Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs. <i>Immune Network</i> , 2020 , 20, e48	6.1	1
282	Prevalence of NUT carcinoma in head and neck: Analysis of 362 cases with literature review. <i>Head and Neck</i> , 2020 , 42, 924-938	4.2	7
281	Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 637-648	8.9	35
280	Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 324-343	8.9	13
279	Junction Location Identifier (JuLI): Accurate Detection of DNA Fusions in Clinical Sequencing for Precision Oncology. <i>Journal of Molecular Diagnostics</i> , 2020 , 22, 304-318	5.1	1
278	Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. <i>Lancet Oncology</i> , 2020 , 21, 261-270	21.7	154
277	Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). <i>Journal of Clinical Oncology</i> , 2020 , 38, 488-495	2.2	121
276	Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study. <i>Journal of Clinical Oncology</i> , 2020 , 38, 538-547	2.2	113
275	Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 404-415	8.9	53
274	Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests. <i>Clinical Lung Cancer</i> , 2020 , 21, e182-e190	4.9	3

273	Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer. <i>Cancer</i> , 2020 , 126, 373-380	6.4	47
272	Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity 2020 , 8,		2
271	Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon Mutations: Are They Different from Those with Common Mutations?. <i>Biology</i> , 2020 , 9,	4.9	3
270	Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 3359-3369	4.9	5
269	An increase of CD8 T cell infiltration following recurrence is a good prognosticator in HNSCC. <i>Scientific Reports</i> , 2020 , 10, 20059	4.9	14
268	The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020 , 9, 1749-1758	4.4	4
267	Metabolic radiogenomics in lung cancer: associations between FDG PET image features and oncogenic signaling pathway alterations. <i>Scientific Reports</i> , 2020 , 10, 13231	4.9	5
266	Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea. <i>BMC Cancer</i> , 2020 , 20, 727	4.8	6
265	Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3592-3603 ¹⁰⁴	2.3	104
264	Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumors. <i>Expert Opinion on Investigational Drugs</i> , 2020 , 29, 1059-1067	5.9	1
263	Evaluating entrectinib as a treatment option for non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 1935-1942	4	5
262	Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1758-1766	8.9	28
261	Utility of positron emission-computed tomography for predicting pathological response in resectable oesophageal squamous cell carcinoma after neoadjuvant chemoradiation. <i>European Journal of Cardio-thoracic Surgery</i> , 2020 , 58, 1019-1026	3	
260	Diagnostic accuracy of MR imaging of patients with leptomeningeal seeding from lung adenocarcinoma based on 2017 RANO proposal: added value of contrast-enhanced 2D axial T2 FLAIR. <i>Journal of Neuro-Oncology</i> , 2020 , 149, 367-372	4.8	1
259	Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?. <i>Journal of Thoracic Disease</i> , 2020 , 12, 3796-3803	2.6	6
258	Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer. <i>Investigational New Drugs</i> , 2020 , 38, 360-368	4.3	15
257	Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma 2020 , 15, e0229299		
256	Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma 2020 , 15, e0229299		

255	Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma 2020 , 15, e0229299		
254	Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma 2020 , 15, e0229299		
253	Predictive and Prognostic Value of F-fluorodeoxyglucose Uptake Combined with Thymidylate Synthase Expression in Patients with Advanced Non-Small Cell Lung Cancer. <i>Scientific Reports</i> , 2019 , 9, 12215	4.9	0
252	Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing. <i>European Journal of Cancer</i> , 2019 , 120, 65-74	7.5	16
251	DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. <i>Nature Communications</i> , 2019 , 10, 4278	17.4	109
250	Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1794-1806	8.9	47
249	Dosimetric predictors for postoperative pulmonary complications in esophageal cancer following neoadjuvant chemoradiotherapy and surgery. <i>Radiotherapy and Oncology</i> , 2019 , 133, 87-92	5.3	10
248	Transthoracic Rebiopsy for Mutation Analysis in Lung Adenocarcinoma: Outcomes and Risk Factors for the Acquisition of Nondiagnostic Specimens in 199 Patients. <i>Clinical Lung Cancer</i> , 2019 , 20, e309-e318	4.9	8
247	Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 193-202	8.9	59
246	Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor. <i>Clinical Lung Cancer</i> , 2019 , 20, 215-221	4.9	8
245	Topological Transformation-Based Nanobarcoding for Detection and Enumeration of MicroRNAs and Single Nucleotide Polymorphism. <i>Advanced Biology</i> , 2019 , 3, e1900013	3.5	3
244	Prognostic Impact of Longitudinal Monitoring of Radiomic Features in Patients with Advanced Non-Small Cell Lung Cancer. <i>Scientific Reports</i> , 2019 , 9, 8730	4.9	7
243	Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma. <i>Lung Cancer</i> , 2019 , 134, 7-15	5.9	21
242	Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1134-1155	8.9	47
241	Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2518-2527	2.2	424
240	Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma 2019 , 7, 128		13
239	Histopathologic characteristics of advanced-stage ROS1-rearranged non-small cell lung cancers. <i>Pathology Research and Practice</i> , 2019 , 215, 152441	3.4	6
238	Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 793-801	8.9	28

237	Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019 , 145, 1341-1349	4.9	13
236	Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. <i>Lancet Respiratory Medicine</i> , 2019 , 7, 347-357	35.1	88
235	Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer. <i>Lung Cancer</i> , 2019 , 130, 87-92	5.9	25
234	Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019 , 25, 3220-3228	12.9	99
233	Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease. <i>International Journal of Cancer</i> , 2019 , 145, 2433-2439	7.5	11
232	Correlations between metabolic texture features, genetic heterogeneity, and mutation burden in patients with lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 446-454	8.8	40
231	Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib. <i>Cancer Research and Treatment</i> , 2019 , 51, 502-509	5.2	45
230	Nanobarcoding: Topological Transformation-Based Nanobarcoding for Detection and Enumeration of MicroRNAs and Single Nucleotide Polymorphism (Adv. Biosys. 7/2019). <i>Advanced Biology</i> , 2019 , 3, 1970072	3.5	
229	Circulating DNAs, a Marker of Neutrophil Extracellular Traposis and Cancer-Related Stroke: The OASIS-Cancer Study. <i>Stroke</i> , 2019 , 50, 2944-2947	6.7	19
228	DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1640-1650	8.9	36
227	Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1608-1618	8.9	47
226	Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study. <i>Lancet Oncology</i> , 2019 , 20, 1681-1690	21.7	47
225	Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2019 , 20, 1506-1517	21.7	344
224	Antitumor activity and safety of MK-1308 (anti-CTLA-4) plus pembrolizumab (pembro) in patients (pts) with non-small cell lung cancer (NSCLC): Updated interim results from a phase I study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2558-2558	2.2	1
223	Pembrolizumab (pembro) for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of phase 3 KEYNOTE-040 prior radiation treatment (RT) and disease state.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 6026-6026	2.2	0
222	Influence of tumor size and Eastern Cooperative Oncology Group performance status (ECOG PS) at baseline on patient (pt) outcomes in lenvatinib-treated radioiodine-refractory differentiated thyroid cancer (RR-DTC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 6081-6081	2.2	5
221	Biomarker driven phase II umbrella trial study of AZD1775, AZD2014, AZD2811 monotherapy in relapsed small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 8514-8514	2.2	6
220	Phase II, prospective single-arm study of adjuvant pembrolizumab in N2 positive non-small cell lung cancer (NSCLC) treated with neoadjuvant concurrent chemoradiotherapy followed by curative resection: Preliminary results.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 8520-8520	2.2	2

219	Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9011-9011 ^{2,3} 4 ²		
218	Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9016-9016	2.2	9
217	Brigatinib (BRG) versus crizotinib (CRZ) in Asian versus non-Asian patients (pts) in the phase III ALTA-1L trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9026-9026	2.2	3
216	Patient-reported outcomes (PROs) with first-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic NSCLC: Results from MYSTIC.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9048-9048	2.2	2
215	Deep learning-based predictive biomarker for immune checkpoint inhibitor response in metastatic non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9094-9094	2.2	1
214	Randomized open-label study of M7824 versus pembrolizumab as first-line (1L) treatment in patients with PD-L1 expressing advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS9114-TPS9114	2.2	3
213	Phase 2 study of brigatinib in patients (pts) with anaplastic lymphoma kinase (ALK) positive, advanced non-small cell lung cancer (NSCLC) that progressed on alectinib or ceritinib.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS9115-TPS9115	2.2	3
212	SAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-driven (MET+), locally advanced or metastatic non-small cell lung cancer (NSCLC), following disease progression on osimertinib.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS9119-TPS9119	2.2	18
211	ORION: A Phase 2, randomized, multicenter, double-blind study to assess efficacy and safety of durvalumab+olaparib vs durvalumab alone as maintenance therapy in Stage IV non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS9126-TPS9126	2.2	3
210	Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001.. <i>Journal of Clinical Oncology</i> , 2019 , 37, LBA9015-LBA9015	2.2	4
209	Evaluation of safety and tolerability of durvalumab (D) and tremelimumab (T) in combination with first-line chemotherapy in patients (pts) with esophageal squamous-cell carcinoma (ESCC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 146-146	2.2	4
208	Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Korean Journal of Internal Medicine</i> , 2019 , 34, 1107-1115 ^{2,5}		1
207	Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer. <i>Korean Journal of Internal Medicine</i> , 2019 , 34, 50-59	2.5	9
206	Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma. <i>Cancer Research and Treatment</i> , 2019 , 51, 300-312	5.2	23
205	EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy. <i>Cancer Research and Treatment</i> , 2019 , 51, 493-501	5.2	13
204	Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2019 , 51, 408-412	5.2	11
203	Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea. <i>Cancer Research and Treatment</i> , 2019 , 51, 623-631	5.2	22
202	A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor. <i>Cancer Research and Treatment</i> , 2019 , 51, 718-726	5.2	6

201	Salvage Concurrent Chemo-radiation Therapy for Loco-regional Recurrence Following Curative Surgery of Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2019 , 51, 769-776	5.2	6
200	Randomized open-label study of M7824 versus pembrolizumab as first-line (1L) treatment in patients with PD-L1 expressing advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS127-TPS127	2.2	0
199	Afatinib versus methotrexate as second-line treatment for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) progressing on or after platinum-based therapy: LUX-Head & Neck 3 phase III trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 6024-6024	2.2	1
198	Severe immune-related adverse events in anti-PD-1-treated patients are clustered into distinct subtypes by peripheral blood T-cell profiles.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2564-2564	2.2	
197	10-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea real-time automatically updated data warehouse in health care (UNIVERSE - ROOT study).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 8536-8536	2.2	
196	Incidence of brain metastasis in lung adenocarcinoma at initial diagnosis on the basis of stage and genetic alterations. <i>Lung Cancer</i> , 2019 , 129, 28-34	5.9	14
195	A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105. <i>Cancer Discovery</i> , 2019 , 9, 384-395	24.4	67
194	Pretreatment Tumor 18F-FDG Uptake Improves Risk Stratification Beyond RECIST 1.1 in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer: FDG Uptake and Risk Stratification. <i>Clinical Nuclear Medicine</i> , 2019 , 44, e60-e67	1.7	1
193	The First-week Proliferative Response of Peripheral Blood PD-1CD8 T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors. <i>Clinical Cancer Research</i> , 2019 , 25, 2144-2154	12.9	74
192	Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies. <i>Cancer</i> , 2019 , 125, 892-901	6.4	78
191	Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018 , 13, e34-e36	8.9	18
190	Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: The effect of postoperative adjuvant chemotherapy. <i>Lung Cancer</i> , 2018 , 117, 7-13	5.9	8
189	Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07). <i>British Journal of Cancer</i> , 2018 , 118, 648-653	8.7	13
188	Phase 1b Trial of Ficlatusumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC. <i>Clinical Pharmacology in Drug Development</i> , 2018 , 7, 532-542	2.3	15
187	KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2018 , 13, e29-e31	8.9	16
186	Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 106-111	8.9	130
185	Brigatinib for treatment of anaplastic lymphoma kinase-rearranged metastatic non-small cell lung cancer. <i>Expert Opinion on Orphan Drugs</i> , 2018 , 6, 253-258	1.1	
184	Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea. <i>Lung Cancer</i> , 2018 , 119, 36-41	5.9	5

183	Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial. <i>Lung Cancer</i> , 2018 , 124, 293-297	5.9	10
182	Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1373-1382	8.9	57
181	Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. <i>Cancer Discovery</i> , 2018 , 8, 1227-1236	24.4	194
180	Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1106-1112	8.9	23
179	Deciphering Clinicoradiologic Phenotype for Thymidylate Synthase Expression Status in Patients with Advanced Lung Adenocarcinoma Using a Radiomics Approach. <i>Scientific Reports</i> , 2018 , 8, 8968	4.9	9
178	A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2513-2513	2.2	11
177	Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs standard of care (SOC) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in KEYNOTE-040.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 6013-6013	2.2	10
176	Early clearance of plasma EGFR mutations as a predictor of response to osimertinib in the AURA3 trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9027-9027	2.2	18
175	4-year overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9030-9030	2.2	10
174	YH25448, a 3rd generation EGFR-TKI, in patients with EGFR-TKI-resistant NSCLC: Phase I/II study results.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9033-9033	2.2	2
173	An open-label, multicenter, phase II single arm trial of osimertinib in non-small cell lung cancer patients with uncommon EGFR mutation (KCSG-LU15-09).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9050-9050	2.2	11
172	Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): Efficacy updates and exploratory analysis of CNS ORR and overall ORR by baseline (BL) brain lesion status.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9061-9061	2.2	15
171	Hyperprogression after immunotherapy: Clinical implication and genomic alterations in advanced non-small cell lung cancer patients (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9075-9075	2.2	18
170	Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01). <i>Journal of Pathology and Translational Medicine</i> , 2018 , 52, 148-156	2.9	11
169	Investigating the feasibility of targeted next-generation sequencing to guide the treatment of head and neck squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e18017-e18017	2.2	
168	Clinical outcomes of EGFR exon 20 insertion in advanced NSCLC in Korea.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e21136-e21136	2.2	
167	Monitoring peripheral blood PD-1+CD8+T cells to predict response to anti-PD-1 therapy in solid tumors.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e24115-e24115	2.2	
166	Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and surgery) in patients with stage IIIA (N2) lung cancer. <i>Lung Cancer</i> , 2018 , 115, 89-96	5.9	15

165	SIDR: simultaneous isolation and parallel sequencing of genomic DNA and total RNA from single cells. <i>Genome Research</i> , 2018 , 28, 75-87	9.7	52
164	Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1405-1411	2.2	152
163	Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2693-2701	2.2	87
162	Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3101-3109	2.2	146
161	CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). <i>Journal of Clinical Oncology</i> , 2018 , 36, 2702-2709	2.2	221
160	Clinical outcomes of radiation therapy for clinical T4b oesophageal cancer with airway invasion. <i>Radiation Oncology</i> , 2018 , 13, 245	4.2	1
159	Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model. <i>PLoS ONE</i> , 2018 , 13, e0194730	3.7	14
158	Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01). <i>Cancer</i> , 2017 , 123, 1958-1964	6.4	28
157	Histologic characteristics of thymic adenocarcinomas: Clinicopathologic study of a nine-case series and a review of the literature. <i>Pathology Research and Practice</i> , 2017 , 213, 106-112	3.4	16
156	Osimertinib for the treatment of non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 225-231	4	2
155	Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1288-1296	2.2	363
154	Outcomes of Curative-Intent Surgery and Adjuvant Treatment for Pulmonary Large Cell Neuroendocrine Carcinoma. <i>World Journal of Surgery</i> , 2017 , 41, 1820-1827	3.3	22
153	EGFR TKI combination with immunotherapy in non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2017 , 16, 465-469	4.1	104
152	Association Between Environmental Tobacco Smoke Exposure and the Occurrence of EGFR Mutations and ALK Rearrangements in Never-smokers With Non-Small-cell Lung Cancer: Analyses From a Prospective Multinational ETS Registry. <i>Clinical Lung Cancer</i> , 2017 , 18, 535-542	4.9	8
151	Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors. <i>Investigational New Drugs</i> , 2017 , 35, 782-790	4.3	17
150	Characteristics and outcomes of ALK+ non-small cell lung cancer patients in Korea. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017 , 13, e239-e245	1.9	6
149	Scientific Advances in Thoracic Oncology 2016. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1183-1209	8.9	29
148	Antineutrophil Cytoplasmic Antibody-Associated Rapid Progressive Glomerulonephritis after Pembrolizumab Treatment in Thymic Epithelial Tumor: A Case Report. <i>Journal of Thoracic Oncology</i> , 2017 , 12, e103-e105	8.9	15

147	Fluorescence-coded DNA Nanostructure Probe System to Enable Discrimination of Tumor Heterogeneity via a Screening of Dual Intracellular microRNA Signatures in situ. <i>Scientific Reports</i> , 2017 , 7, 13499	4.9	5
146	Blood Droplet-Based Cancer Diagnosis via Proteolytic Activity Measurement in Cancer Progression. <i>Theranostics</i> , 2017 , 7, 2878-2887	12.1	7
145	Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2490-2498	2.2	366
144	Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3449-3457	2.2	223
143	Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2613-2618	2.2	193
142	A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01). <i>Oncotarget</i> , 2017 , 8, 15943-15951	3.3	9
141	Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer. <i>OncImmunity</i> , 2017 , 7, e1375642	7.2	52
140	An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2017 , 17, 933-942	3.8	3
139	Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers. <i>Lung Cancer</i> , 2017 , 112, 195-199	5.9	7
138	Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 80, 591-598	3.5	34
137	Prevalence and detection of low-allele-fraction variants in clinical cancer samples. <i>Nature Communications</i> , 2017 , 8, 1377	17.4	92
136	Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1806-1813	8.9	16
135	Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types. <i>Supportive Care in Cancer</i> , 2017 , 25, 801-809	3.9	7
134	Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. <i>Clinical Lung Cancer</i> , 2017 , 18, 34-42.e2	4.9	22
133	Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer. <i>Cancer Research and Treatment</i> , 2017 , 49, 906-914	5.2	15
132	Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): Updated results from the BLOOM study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2020-2020	2.2	54
131	CNS response to osimertinib in patients (pts) with T790M-positive advanced NSCLC: Data from a randomized phase III trial (AURA3).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9005-9005	2.2	41
130	KEYNOTE-001: 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9011-9011	2.2	16

129	Updated safety and clinical activity of durvalumab monotherapy in previously treated patients with stage IIIB/IV NSCLC.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9085-9085	2.2	6
128	Factors associated with better overall survival (OS) in patients with previously treated, PD-L1 ⁺ expressing, advanced NSCLC: Multivariate analysis of KEYNOTE-010.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9090-9090	2.2	10
127	Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC) and brain metastases in the pivotal randomized phase 2 ALTA trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20502-e20502	2.2	3
126	Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): Updates from ALTA, a pivotal randomized phase 2 trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20503-e20503	2.2	2
125	Safety and clinical activity of first-line durvalumab in advanced NSCLC: Updated results from a Phase 1/2 study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20504-e20504	2.2	8
124	Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery. <i>Oncotarget</i> , 2017 , 8, 3542-3552	3.3	6
123	A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer. <i>Oncotarget</i> , 2017 , 8, 41474-41486	3.3	12
122	Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center ^B experiences. <i>Oncotarget</i> , 2017 , 8, 42478-42486	3.3	16
121	Mutational status of defines the efficacy of Wee1 inhibitor AZD1775 in -mutant non-small cell lung cancer. <i>Oncotarget</i> , 2017 , 8, 67526-67537	3.3	10
120	Size of Non-lepidic Invasive Pattern Predicts Recurrence in Pulmonary Mucinous Adenocarcinoma: Morphologic Analysis of 188 Resected Cases with Reappraisal of Invasion Criteria. <i>Journal of Pathology and Translational Medicine</i> , 2017 , 51, 56-68	2.9	3
119	Metastatic Squamous Cell Carcinoma from Lung Adenocarcinoma after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy. <i>Journal of Pathology and Translational Medicine</i> , 2017 , 51, 441-443	2.9	5
118	A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma. <i>Cancer Research and Treatment</i> , 2017 , 49, 816-823	5.2	8
117	Efficacy and Safety of First-Line Nectinmab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study. <i>Cancer Research and Treatment</i> , 2017 , 49, 937-946	5.2	7
116	Hypercoagulability and Mortality of Patients with Stroke and Active Cancer: The OASIS-CANCER Study. <i>Journal of Stroke</i> , 2017 , 19, 77-87	5.6	57
115	The feasibility of using small biopsy samples from lung cancer for targeted next-generation sequencing.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20584-e20584	2.2	1
114	Role of Adjuvant Thoracic Radiation Therapy and Full Dose Chemotherapy in pN2 Non-small Cell Lung Cancer: Elucidation Based on Single Institute Experience. <i>Cancer Research and Treatment</i> , 2017 , 49, 880-889	5.2	0
113	Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis. <i>Medical Oncology</i> , 2016 , 33, 97	3.7	30
112	Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2866-73	2.2	238

111	Value of volume-based early metabolic response in patients with unresectable thymic epithelial tumor. <i>Lung Cancer</i> , 2016 , 100, 24-29	5.9	3
110	Value of F-FDG heterogeneity for discerning metastatic from benign lymph nodes in nasopharyngeal carcinoma patients with suspected recurrence. <i>British Journal of Radiology</i> , 2016 , 89, 20160109	3.4	3
109	Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial. <i>Lung Cancer</i> , 2016 , 102, 65-73	5.9	61
108	Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study. <i>Cancer Imaging</i> , 2016 , 16, 5	5.6	19
107	Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review. <i>Oral Oncology</i> , 2016 , 53, 10-6	4.4	55
106	Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment. <i>Journal of Thoracic Oncology</i> , 2016 , 11, e1-4	8.9	59
105	Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016 , 11, e45-7	8.9	82
104	Pembrolizumab for the treatment of non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 397-406	5.4	52
103	Different clinical outcomes between locally advanced hypopharyngeal and oropharyngeal cancer treated with definitive concurrent chemoradiotherapy: implication for subgroup selection for induction chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2016 , 46, 40-5	2.8	7
102	First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase III Trial. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 278-9	8.9	11
101	First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study. <i>JAMA Oncology</i> , 2016 , 2, 305-12	13.4	164
100	Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02). <i>Radiotherapy and Oncology</i> , 2016 , 118, 244-50	5.3	27
99	A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib. <i>Clinical Cancer Research</i> , 2016 , 22, 2139-45	12.9	25
98	Archival vs new tumor samples for assessing PD-L1 expression in the KEYNOTE-010 study of pembrolizumab (pembro) vs docetaxel (doce) for previously treated advanced NSCLC.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3030-3030	2.2	3
97	Phase II trial of nintedanib in patients with recurrent or metastatic salivary gland cancer: A multicenter phase II study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 6090-6090	2.2	1
96	Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): Updated results from BLOOM, a phase I study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9002-9002	2.2	53
95	Phase I study of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-small-cell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal metastasis (LM).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9003-9003	2.2	16
94	Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9007-9007	2.2	21

93	A phase II study of vandetanib in patients with non-small cell lung cancer harboring RET rearrangement.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9013-9013	2.2	11
92	Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9022-9022	2.2	14
91	Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9026-9026	2.2	25
90	Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non-small-cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9029-9029	2.2	26
89	Addition of HSP90 inhibitor onalespib to crizotinib prior to progression in patients with ALK-pos NSCLC: Results of a randomized phase 2 study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9059-9059	2.2	1
88	Activity of brigatinib (BRG) in crizotinib (CRZ) resistant patients (pts) according to ALK mutation status.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9060-9060	2.2	11
87	A phase 3, randomized, open-label study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC; EXTREME regimen) in recurrent/metastatic (R/M) SCCHN: KESTREL.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS6101-TPS6101	2.2	19
86	Integrated genomic approaches identify upregulation of SCRNI as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation. <i>Oncotarget</i> , 2016 , 7, 13797-809	3.3	5
85	Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium). <i>Oncotarget</i> , 2016 , 7, 36311-36320	3.3	36
84	Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases. <i>Journal of Pathology and Translational Medicine</i> , 2016 , 50, 197-203	2.9	57
83	Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases. <i>Journal of Pathology and Translational Medicine</i> , 2016 , 50, 258-63	2.9	34
82	Current Status and Challenges of Cancer Clinical Trials in Korea. <i>Cancer Research and Treatment</i> , 2016 , 48, 20-7	5.2	9
81	Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial. <i>Cancer Research and Treatment</i> , 2016 , 48, 458-64	5.2	1
80	Association Between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma. <i>Cancer Research and Treatment</i> , 2016 , 48, 527-36	5.2	90
79	Combination of CDK4/6 inhibitor, LY2835219, and mTOR inhibitor to synergistically suppress the growth of head and neck squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e14118-e14118 ²	2.2	11
78	Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). <i>Oncotarget</i> , 2016 , 7, 6984-93	3.3	115
77	The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations. <i>Journal of Thoracic Disease</i> , 2016 , 8, 3175-3186	2.6	3
76	Cancer Cell-Derived Extracellular Vesicles Are Associated with Coagulopathy Causing Ischemic Stroke via Tissue Factor-Independent Way: The OASIS-CANCER Study. <i>PLoS ONE</i> , 2016 , 11, e0159170	3.7	30

75	The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2016 , 7, 14803-13	3.3	37
74	An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016 , 12, 386-387	1.9	3
73	Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study. <i>Cancer</i> , 2016 , 122, 3024-31	6.4	56
72	Fate of patients with nasopharyngeal cancer who developed distant metastasis as first failure after definitive radiation therapy. <i>Head and Neck</i> , 2016 , 38 Suppl 1, E293-9	4.2	3
71	AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases. <i>Science Translational Medicine</i> , 2016 , 8, 368ra172	17.5	58
70	Assessment of objective responses in thymic epithelial tumors using ITMIG modified criteria. <i>Lung Cancer</i> , 2016 , 96, 48-51	5.9	4
69	Reply to E. Giovannetti et al. <i>Journal of Clinical Oncology</i> , 2016 , 34, 512-3	2.2	2
68	AZD9291 overcomes T790M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells. <i>Investigational New Drugs</i> , 2016 , 34, 407-15	4.3	11
67	Outcomes of neoadjuvant concurrent chemoradiotherapy followed by surgery for non-small-cell lung cancer with N2 disease. <i>Lung Cancer</i> , 2016 , 96, 56-62	5.9	26
66	Do New pN Subclassifications Proposed by IASLCB Lung Cancer Staging Project Agree with ypN Categories after Trimodality Therapy for Initial N2 Disease?. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 2202-2207 ³	8.9	3
65	Outcomes of Gamma Knife Radiosurgery in Combination with Crizotinib for Patients with Brain Metastasis from Non-Small Cell Lung Cancer. <i>World Neurosurgery</i> , 2016 , 95, 399-405	2.1	5
64	Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. <i>Clinical Cancer Research</i> , 2015 , 21, 544-52	12.9	45
63	Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2450-6	2.2	55
62	Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. <i>Lancet Oncology</i> , 2015 , 16, 990-8	21.7	291
61	Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy. <i>Clinical Lung Cancer</i> , 2015 , 16, 228-36	4.9	20
60	Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2660-6	2.2	170
59	Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer. <i>American Journal of Roentgenology</i> , 2015 , 205, 623-8	5.4	18
58	Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs. <i>Lung Cancer</i> , 2015 , 90, 261-6	5.9	4

57	Outcome of gamma knife radiosurgery for metastatic brain tumors derived from non-small cell lung cancer. <i>Journal of Neuro-Oncology</i> , 2015 , 125, 331-8	4.8	18
56	Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer. <i>PLoS Genetics</i> , 2015 , 11, e1005467	6	86
55	Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea. <i>Lung Cancer</i> , 2015 , 87, 148-54	5.9	59
54	Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2509-2509	2.2	24
53	Phase I trial and pharmacokinetic study of Tanibirumab, a fully human monoclonal antibody to the vascular endothelial growth factor receptor 2 in patients with refractory solid tumors.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2522-2522	2.2	1
52	Clinical trials outcomes of combined BKM120 and cetuximab compared to BKM120 in recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M-SCCHN).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 6049-6049	2.2	3
51	AZD3759, an EGFR inhibitor with blood brain barrier (BBB) penetration for the treatment of non-small cell lung cancer (NSCLC) with brain metastasis (BM): Preclinical evidence and clinical cases.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8016-8016	2.2	15
50	Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1 β positive metastatic non-small cell lung cancer (NSCLC): Updated data from KEYNOTE-001.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8026-8026	2.2	9
49	A randomized Phase 3 study comparing first-line pemetrexed plus cisplatin followed by gefitinib maintenance (PC/G) with gefitinib monotherapy (G) in East Asian patients (pts) with locally advanced or metastatic nonsquamous non-small cell lung cancer (nSqNSCLC): Final survival results.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8041-8041	2.2	1
48	ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8059-8059	2.2	39
47	Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8073-8073	2.2	4
46	A phase Ib/II study of afatinib in combination with nimotuzumab in non-small cell lung cancer patients with acquired resistance to gefitinib or erlotinib.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8086-8086	2.2	1
45	The prevalence and prognostic relevance of PD-L1 expression in patients with HPV-negative and HPV-positive oropharyngeal cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e14003-e14003	2.2	1
44	Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer. <i>Oncotarget</i> , 2015 , 6, 30929-38	3.3	9
43	The NEXT-1 (Next generation pErsonalized tX with mULTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis. <i>Oncotarget</i> , 2015 , 6, 33358-68	3.3	21
42	Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2015 , 6, 44971-84	3.3	10
41	Prognostic value of volume-based positron emission tomography/computed tomography in patients with nasopharyngeal carcinoma treated with concurrent chemoradiotherapy. <i>Clinical and Experimental Otorhinolaryngology</i> , 2015 , 8, 142-8	3.4	21
40	Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma. <i>World Journal of Gastroenterology</i> , 2015 , 21, 4268-74	5.6	7

39	Pemetrexed Continuation Maintenance in Patients with Nonsquamous Non-small Cell Lung Cancer: Review of Two East Asian Trials in Reference to PARAMOUNT. <i>Cancer Research and Treatment</i> , 2015 , 47, 424-35	5.2	4
38	Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2015 , 47, 645-52	5.2	5
37	Dynamic serial monitoring of EGFR mutations in plasma DNA samples in EGFR mutant NSCLC patients treated with EGFR TKI.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8078-8078	2.2	3
36	A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer. <i>Journal of Molecular Diagnostics</i> , 2014 , 16, 229-43	5.1	89
35	First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial. <i>European Journal of Cancer</i> , 2014 , 50, 2219-30	7.5	29
34	A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin. <i>Lung Cancer</i> , 2014 , 84, 51-5	5.9	24
33	Quantitative CT variables enabling response prediction in neoadjuvant therapy with EGFR-TKIs: are they different from those in neoadjuvant concurrent chemoradiotherapy?. <i>PLoS ONE</i> , 2014 , 9, e88598	3.7	38
32	Molecular Targeted Therapy in Lung Cancer. <i>Hanyang Medical Reviews</i> , 2014 , 34, 37		1
31	Phase II study of Afatinib as third-line treatment for patients in Korea with stage IIIB/IV non-small cell lung cancer harboring wild-type EGFR. <i>Oncologist</i> , 2014 , 19, 702-3	5.7	10
30	Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR- β -, NTRK1-) Non-Small Cell Lung Cancer Globally?. <i>Frontiers in Oncology</i> , 2014 , 4, 58	5.3	20
29	Pleural mesothelioma: an institutional experience of 66 cases. <i>Korean Journal of Pathology</i> , 2014 , 48, 91-9		4
28	Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma. <i>Lung Cancer</i> , 2014 , 83, 259-64	5.9	26
27	Phase Ib/II study of the PI3K β inhibitor BYL719 in combination with cetuximab in recurrent/metastatic squamous cell cancer of the head and neck (SCCHN).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6044-6044	2.2	13
26	A multinational phase III randomized trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small cell lung cancer (CChEN).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7500-7500	2.2	3
25	Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8009-8009	2.2	63
24	Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with EGFR-mutated (mut), MET-positive NSCLC: A single-arm phase Ib/II study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8017-8017	2.2	27
23	Tivantinib plus erlotinib versus placebo plus erlotinib in Asian patients with previously treated nonsquamous NSCLC with wild-type EGFR: First report of a phase III ATTENTION trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8044-8044	2.2	8
22	The presence of ALK translocation in sarcomatoid carcinoma of head and neck and treatment effect of crizotinib: A case series.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e17048-e17048	2.2	

21	Comparison of concurrent chemoradiation therapy with 3-weekly versus weekly cisplatin in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II noninferiority trial (KCSG-HN10-02).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6023-6023	2.2	
20	Evaluation of biochemical features of anemia in cancer patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e20698-e20698	2.2	1
19	Impact of environmental tobacco smoke (ETS) on ALK rearrangements in never smokers (NS) with non-small cell lung cancer (NSCLC): Analyses on a prospective multinational ETS registry.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 7565-7565	2.2	1
18	MEK114653: A randomized, multicenter, phase II study to assess efficacy and safety of trametinib (T) compared with docetaxel (D) in KRAS-mutant advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8029-8029	2.2	14
17	Lume-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8024-8024	2.2	35
16	CA184-104: Randomized, multicenter, double-blind, phase III trial comparing the efficacy of ipilimumab (Ipi) with paclitaxel/carboplatin (PC) versus placebo with PC in patients (pts) with stage IV/recurrent non-small cell lung cancer (NSCLC) of squamous histology.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1533-1533	2.2	2
15	Tumor lysis syndrome in a solid tumor: a case report of a patient with invasive thymoma. <i>Cancer Research and Treatment</i> , 2013 , 45, 343-8	5.2	4
14	Roles of cMET/ErbB3 activation and overexpression in the development of resistance to EGFR inhibitors in NSCLC patients.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 11113-11113	2.2	
13	Comparison of clinical outcome between gefitinib and erlotinib treatment in patients with non-small cell lung cancer harboring an epidermal growth factor receptor exon 19 or exon 21 mutations.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e19051-e19051	2.2	
12	The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populations. <i>Human Genetics</i> , 2012 , 131, 365-72	6.3	41
11	A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK. <i>Journal of Thoracic Oncology</i> , 2012 , 7, e36-e38	8.9	77
10	Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2012 , 77, 346-52	5.9	22
9	The effectiveness of maintenance pharmacotherapies for non-small cell lung cancer. <i>Clinical Medicine Insights: Oncology</i> , 2012 , 6, 253-62	1.8	1
8	Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7533-7533	2.2	45
7	ASPIRATION: Phase II study of continued erlotinib beyond RECIST progression in Asian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, TPS7614-TPS7614	2.2	7
6	A Single Nucleotide Polymorphism in the Phospholipase D1 Gene is Associated with Risk of Non-Small Cell Lung Cancer. <i>International Journal of Biomedical Science</i> , 2012 , 8, 121-8		11
5	A prospective, phase II trial of induction chemotherapy with docetaxel/cisplatin for Masaoka stage III/IV thymic epithelial tumors.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7104-7104	2.2	
4	Comparison of clinical outcomes between concurrent chemoradiotherapy followed by adjuvant chemotherapy and concurrent chemoradiotherapy alone for patients associated with locally advanced nasopharyngeal carcinoma: A retrospective analysis of single center experience.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e16003-e16003	2.2	

- 3 Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan. *Asia-Pacific Journal of Clinical Oncology*, **2011**, 7 Suppl 2, 22-33 1.9 19
- 2 Organ Preservation for the Management of Locally Advanced Head and Neck Cancer. *Hanyang Medical Reviews*, **2009**, 29, 198
- 1 Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer?. *Clinical Cancer Research*, **2008**, 14, 3860-6 12.9 47